LIDOCAINE ointment

País: Estats Units

Idioma: anglès

Font: NLM (National Library of Medicine)

ingredients actius:

LIDOCAINE (UNII: 98PI200987) (LIDOCAINE - UNII:98PI200987)

Disponible des:

MARTIN EKWEALOR PHARMACEUTICALS, INC.

Designació comuna internacional (DCI):

LIDOCAINE

Composición:

LIDOCAINE 2.5 g in 50 g

Vía de administración:

TOPICAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. Lidocaine USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of Lidocaine Ointment USP, 5%.

Resumen del producto:

Lidocaine Ointment USP, 5% is supplied as a white color ointment. It is available as follows: 50 g (1 3/4 oz) double wall jar, NDC 58607-918-53. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled RoomTemperature]. Manufactured by: ME Pharmac Rev. 01/17

Estat d'Autorització:

unapproved drug other

Fitxa tècnica

LIDOCAINE- LIDOCAINE OINTMENT
MARTIN EKWEALOR PHARMACEUTICALS, INC.
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
LIDOCAINE OINTMENT - 918
LIDOCAINE OINTMENT USP, 5%
FOR TOPICAL USE ONLY
Rx Only DESCRIPTION
Lidocaine Ointment USP, 5% idocaine Ointment USP, 5% contains a local
anesthetic agent and is
administered topically. See INDICATIONS AND USAGE for specific uses.
Lidocaine Ointment USP,
5% contains lidocaine, USP, which is chemically designated as
acetamide, 2-(diethylamino)-N-(2,6-
dimethylphenyl)-, and has the following structural formula:
Composition of Lidocaine Ointment USP, 5%: acetamide,
2-(diethylamino)-N-(2,6-dimethylphenyl)-,
(lidocaine) 5% in a water miscible ointment vehicle containing
polyethylene glycols.
CLINICAL PHARMACOLOGY
Mechanism of action: Lidocaine stabilizes the neuronal membrane by
inhibiting the ionic fluxes required
for the initiation and conduction of impulses, thereby effecting local
anesthetic action.
Onset of anesthesia: Lidocaine Ointment 5% effects local, topical
anesthesia. The onset of action is 3 to
5 minutes. It is ineffective when applied to intact skin.
Hemodynamics: Excessive blood levels may cause changes in cardiac
output, total peripheral
resistance, and mean arterial pressure. These changes may be
attributable to a direct depressant effect
of the local anesthetic agent on various components of the
cardiovascular system.
Pharmacokinetics and metabolism: Lidocaine may be absorbed following
topical administration to
mucous membranes, its rate and extent of absorption depending upon the
specific site of application,
duration of exposure, concentration, and total dosage. In general, the
rate of absorption of local
anesthetic agents following topical application occurs most rapidly
after intratracheal administration.
Lidocaine is also well-absorbed from the gastrointestinal tract, but
little intact drug appears in the
circu